Chief Financial Officer

Headquartered in Auckland, Aroa Biosurgery is a global soft tissue regeneration company dedicated to unlocking regenerative healing through its patented AROA ECM™ wound and tissue reconstruction products. Founded in 2008 and listed on the ASX, Aroa has established US operations, regulatory approval in over 50 countries, and employs more than 260 people across New Zealand and North America. To date, over 7 million AROA ECM™ devices have been used worldwide. Reporting directly to Founder and CEO, the CFO leads finance, investor relations and commercial support as Aroa scales its global growth.

Responsibilities

Lead financial reporting, budgeting, forecasting and long-term planning across the group; Own investor relations and capital markets communications, including ASX disclosures and the annual roadshow; Provide commercial support and decision-making input as the business scales, including modelling for new markets and partners; Partner with the incoming CCO and GM Commercial Ops as new commercial leadership is established; Lead financial due diligence and integration for M&A and strategic partnerships; Maintain strong governance, working with the Audit & Risk and Remuneration committees; Build a high-performing, well-structured finance team with stronger leadership presence

Requirements

Current CFO or experienced Deputy/Divisional CFO within a larger, complex organisation, not a first-time CFO; Proven experience leading finance within a global, high-growth business; Listed company experience essential; Strong capital markets, investor relations and Board reporting experience; A commercial, data-driven operator who is also a genuine people leader

Nice to have

ASX exposure; Significant US market exposure, including the cultural dimension of a US customer base; MedTech, life sciences or healthcare experience

Benefits

Competitive base plus STI and LTI; Hybrid working, 4 days on-site and 1 day from home; Direct exposure to the Founder/CEO, Board and Executive Leadership Team; Genuine breadth across finance, IR, M&A and commercial support